Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030


Summary

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

According to APO Research, The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Amylin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.

Glucagon Like Peptide-1 (GLP-1) Agonists segment by Company

Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Glucagon Like Peptide-1 (GLP-1) Agonists segment by Type

Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Glucagon Like Peptide-1 (GLP-1) Agonists segment by Application

Hospital
Pharmacy
Other
Glucagon Like Peptide-1 (GLP-1) Agonists segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glucagon Like Peptide-1 (GLP-1) Agonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, 2019 VS 2023 VS 2030
1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts (2019-2030)
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts (2019-2030)
1.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Manufacturers
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2019-2024)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2019-2024)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Sales Price by Manufacturers (2019-2024)
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers, Product Type & Application
3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
3.8.2 Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2023
3.8.3 2023 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier 3
4 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Type Introduction
4.1.1 Exenatied
4.1.2 Liraglutide
4.1.3 Lixisenatide
4.1.4 Albiglutide
4.1.5 Dulaglutide
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
5 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Application Introduction
5.1.1 Hospital
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application
5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
5.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2030)
6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024)
6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
7.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024)
7.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030)
7.1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030)
7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030)
7.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030)
7.4.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030)
7.5.2 LAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2019 VS 2023 VS 2030
8 Company Profiles
8.1 Novo Nordisk
8.1.1 Novo Nordisk Comapny Information
8.1.2 Novo Nordisk Business Overview
8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.1.5 Novo Nordisk Recent Developments
8.2 AstraZeneca
8.2.1 AstraZeneca Comapny Information
8.2.2 AstraZeneca Business Overview
8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.2.5 AstraZeneca Recent Developments
8.3 Eli Lily
8.3.1 Eli Lily Comapny Information
8.3.2 Eli Lily Business Overview
8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.3.5 Eli Lily Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.4.5 GSK Recent Developments
8.5 Sanofi
8.5.1 Sanofi Comapny Information
8.5.2 Sanofi Business Overview
8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.5.5 Sanofi Recent Developments
8.6 Bristol-Myers Squibb
8.6.1 Bristol-Myers Squibb Comapny Information
8.6.2 Bristol-Myers Squibb Business Overview
8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.6.5 Bristol-Myers Squibb Recent Developments
8.7 Amylin
8.7.1 Amylin Comapny Information
8.7.2 Amylin Business Overview
8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.7.5 Amylin Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
9.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
9.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings